DMSO, a natural compound derived from trees, has been touted as a potential breakthrough in medicine for its ability to aid tissue regeneration, reverse inflammation, and relieve chronic pain. Despite over 11,000 scientific studies documenting its therapeutic effects since the 1960s, DMSO remains heavily restricted, with critics attributing its suppression to the influence of pharmaceutical giants.

DMSO functions as a polar solvent, capable of dissolving and transporting both water-soluble and fat-soluble compounds deep into tissues. When applied topically or ingested, it has been linked to various health benefits, including the induction of cancer cell death in clinical studies. A 2014 study published in Cancer Letters reported that DMSO combined with hematoxylin achieved complete remission in cervical cancer patients by triggering apoptosis. However, such findings have been overshadowed by regulatory barriers.

Veterinarians and sports medicine professionals have long utilized DMSO to treat injuries in animals and athletes, citing its effectiveness without significant side effects. Meanwhile, the FDA has restricted its human use despite approving other pharmaceuticals with higher risks, such as opioids. Proponents argue that DMSO’s affordability and natural origin threaten the profitability of synthetic drugs, leading to its marginalization.

The compound’s regenerative properties have also drawn attention, with research suggesting it can stimulate stem cells and neuroplasticity. Critics claim DMSO outperforms traditional treatments like chemotherapy at a fraction of the cost, yet regulatory agencies continue to block its widespread availability.

Despite these challenges, advocates emphasize that the human body possesses innate healing capabilities, which they believe can be enhanced through natural compounds like DMSO. The debate over its legitimacy persists, with calls for further research and transparency in medical regulations.